ArticleACS nano2023
Cationic Carrier Mediated Delivery of Anionic Contrast Agents in Low Doses Enable Enhanced Computed Tomography Imaging of Cartilage for Early Osteoarthritis Diagnosis.
Article in ACS nano, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- Protein-based nanocarrier delivering kartogenin derivative to cartilage matrix for intra-articular treatment of osteoarthritis.Journal of drug delivery science and technology · 2026Article
- Peptide-based targeted drug delivery strategies for osteoarthritis treatment.npj biomedical innovations · 2026Review
- Engineered cationic Interleukin-1 receptor antagonist outperforms anakinra at joint retention and preventing IL-1-induced cartilage inflammation.Osteoarthritis and cartilage · 2026Article
- Article
- Article
- Spatial charge-hydrophobicity configuration modulates cationic peptide transport in cartilage.Biophysical journal · 2025Article
- Cationic Peptoids for Systemic In Vivo Cartilage-Targeting.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Intelligent microstructure materials for diagnosis and treatment of osteoarthritis: progress and AI-enpowered future.Bone research · 2025Review
- Nanoparticle-enabled molecular imaging diagnosis of osteoarthritis.Materials today. Bio · 2025Review
- Cartilage-targeting exosomes for delivery of receptor antagonist of interleukin-1 in osteoarthritis treatment.Osteoarthritis and cartilage · 2025Article
- A Supramolecular, Triple Negative Breast Cancer-Targeting Avidin-Photosensitizer.Macromolecular bioscience · 2025Article
- Cartilage targeting cationic peptide carriers display deep cartilage penetration and retention in a rabbit model of post-traumatic osteoarthritis.Osteoarthritis and cartilage · 2025Article
- Nanomaterials in the diagnosis and therapy of osteoarthritis: current research advances and future clinical prospects.Frontiers in bioengineering and biotechnology · 2025Review
- Modular iodinated carboxybetaine copolymers as charge-sensitive contrast agents for the detection of cartilage degradation.Materials today. Bio · 2024Article
- Targeted K-Edge Nanoprobes From Praseodymium and Hafnium for Ratiometric Tracking of Dual Biomarkers using Spectral Photon Counting CT.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Harnessing exosomes for advanced osteoarthritis therapy.Nanoscale · 2024Review
- Tamarixetin Protects Chondrocytes against IL-1β-Induced Osteoarthritis Phenotype by Inhibiting NF-κB and Activating Nrf2 Signaling.Antioxidants (Basel, Switzerland) · 2024Article
- Charge-Reversed Exosomes for Targeted Gene Delivery to Cartilage for Osteoarthritis Treatment.Small methods · 2024Article
- Iodinated gadolinium-gold nanomaterial as a multimodal contrast agent for cartilage tissue imaging.APL bioengineering · 2024Article
- Cationic-motif-modified exosomes for mRNA delivery to retinal photoreceptors.Journal of materials chemistry. B · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Cartilage tissue exhibits early degenerative changes with onset of osteoarthritis (OA). Early diagnosis is critical as there is only a narrow time window during which therapeutic intervention can reverse disease progression. Computed tomography (CT) has been considered for cartilage imaging as a tool for early OA diagnosis by introducing radio-opaque contrast agents like ioxaglate (IOX) into the joint. IOX, however, is anionic and thus repelled by negatively charged cartilage glycosaminoglycans (GAGs) that hinders its intra-tissue penetration and partitioning, resulting in poor CT attenuation. This is further complicated by its short intra-tissue residence time owing to rapid clearance from joints, which necessitates high doses causing toxicity concerns. Here we engineer optimally charged cationic contrast agents based on cartilage negative fixed charge density by conjugating cartilage targeting a cationic peptide carrier (CPC) and multi-arm avidin nanoconstruct (mAv) to IOX, such that they can penetrate through the full thickness of cartilage within 6 h using electrostatic interactions and elicit similar CT signal with about 40× lower dose compared to anionic IOX. Their partitioning and distribution correlate strongly with spatial GAG distribution within healthy and early- to late-stage arthritic bovine cartilage tissues at 50-100× lower doses than other cationic contrast agents used in the current literature. The use of contrast agents at low concentrations also allowed for delineation of cartilage from subchondral bone as well as other soft tissues in rat tibial joints. These contrast agents are safe to use at current doses, making CT a viable imaging modality for early detection of OA and staging of its severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.